Earnings Previews: AbbVie, Cameco, Canopy Growth, PepsiCo, Under Armour
- By247wallst-
Before U.S. markets open on Thursday, AbbVie, Cameco, Canopy Growth, PepsiCo and Under Armour will report quarterly earnings.
Before U.S. markets open on Thursday, AbbVie, Cameco, Canopy Growth, PepsiCo and Under Armour will report quarterly earnings.
By Sam Boughedda AbbVie (NYSE:ABBV) is looking towards its new drugs to replace Humira now that its blockbuster immune-disease therapy is facing lower-priced competition, the Wall...
By Peter Nurse Investing.com -- Stocks in focus in premarket trade on Monday, February 6th. Please refresh for updates. Dell Technologies (NYSE:DELL) stock rose 1.5% after...
The prospects of three stocks that are ideal for rising passive income.
Rising rates, accelerating inflation, and slowing economy hammered S&P 500 Energy and healthcare shares have been the market’s top gainers Investors should consider...
EU attempting to revive Iran nuclear deal with market staying pessimistic Crude prices could rebound from oversold conditions but stay off 2022 highs Both Iran, US likely looking...
AbbVie Inc. is a research-based biopharmaceutical company, which is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. It offers products in various therapeutic categories, including immunology products, which include Humira, Skyrizi and Rinvoq; oncology products, which include Imbruvica and Venclexta; aesthetics products that include Botox Cosmetic, Juvederm Collection and others; neuroscience products, such as Botox Therapeutic, Vraylar, Duopa and Duodopa, and Ubrelvy; eye care products consists of Lumigan, Alphagan and Restasis; women's health products include Lo Loestrin, Orilissa and others; and other products, which includes Mavyret, Creon, Lupron, Linzess and Synthroid. Its products are sold to wholesalers, government agencies, health care facilities and independent retailers. It also discovers and develop antibody medicines that target difficult-to-drug disease-causing proteins, such as G protein-coupled receptors (GPCRs).
| Average | 163.00 (+12.72% Upside) |
| High | 200.00 |
| Low | 135.00 |
| Price | 144.61 |
| No. of Analysts | 23 |
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Buy |
| Technical Indicators | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Buy |
| Summary | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 48.02 | 48.02 | 47.65 | -0.080 | -0.17% | 1.46M | Sydney | |||
| 216.15 | 216.35 | 215.01 | -0.23 | -0.11% | 11.30K | Sydney | |||
| 4.04 | 4.13 | 4.02 | 0.00 | 0.00% | 0.00 | Sydney | |||
| 308.48 | 308.88 | 305.30 | +2.28 | +0.74% | 63.82K | Sydney | |||
| 0.36 | 0.38 | 0.37 | -0.01 | -2.67% | 6.03K | Sydney | |||
| 0.027 | 0.028 | 0.027 | 0.00 | 0.00% | 0.00 | Sydney | |||
| 109.78 | 110.24 | 109.59 | -0.540 | -0.49% | 243.28K | Sydney | |||
| 4.57 | 4.58 | 4.55 | -0.010 | -0.22% | 231.11K | Sydney | |||
| 25.93 | 25.97 | 25.70 | +0.140 | +0.54% | 930.60K | Sydney | |||
| 0.013 | 0.014 | 0.014 | +0.001 | +3.85% | 6.27M | Sydney | |||
| 0.19 | 0.19 | 0.19 | +0.005 | +2.70% | 259.00 | Sydney | |||
| 194.82 | 195.46 | 194.31 | -0.410 | -0.21% | 77.70K | Sydney | |||
| 1.21 | 1.24 | 1.205 | 0.00 | 0.00% | 65.14K | Sydney | |||
| 0.915 | 0.92 | 0.915 | 0.00 | 0.00% | 0.00 | Sydney | |||
| 0.041 | 0.041 | 0.041 | 0.00 | 0.00% | 0.00 | Sydney |